NZ721089A - Angiotensin ii alone or in combination for the treatment of hypotension - Google Patents

Angiotensin ii alone or in combination for the treatment of hypotension

Info

Publication number
NZ721089A
NZ721089A NZ721089A NZ72108914A NZ721089A NZ 721089 A NZ721089 A NZ 721089A NZ 721089 A NZ721089 A NZ 721089A NZ 72108914 A NZ72108914 A NZ 72108914A NZ 721089 A NZ721089 A NZ 721089A
Authority
NZ
New Zealand
Prior art keywords
angiotensin
mcg
dose
equivalent
treatment
Prior art date
Application number
NZ721089A
Other languages
English (en)
Inventor
Lakhmir Chawla
Original Assignee
The George Washington Univ A Congressional Chartered Not For Profit Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53367119&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ721089(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by The George Washington Univ A Congressional Chartered Not For Profit Corporation filed Critical The George Washington Univ A Congressional Chartered Not For Profit Corporation
Publication of NZ721089A publication Critical patent/NZ721089A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/085—Angiotensins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NZ721089A 2013-12-18 2014-12-18 Angiotensin ii alone or in combination for the treatment of hypotension NZ721089A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361917576P 2013-12-18 2013-12-18
US201461955706P 2014-03-19 2014-03-19
PCT/US2014/071186 WO2015095535A1 (en) 2013-12-18 2014-12-18 Angiotensin ii alone or in combination for the treatment of hypotension

Publications (1)

Publication Number Publication Date
NZ721089A true NZ721089A (en) 2022-10-28

Family

ID=53367119

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ721089A NZ721089A (en) 2013-12-18 2014-12-18 Angiotensin ii alone or in combination for the treatment of hypotension

Country Status (25)

Country Link
US (7) US9220745B2 (enExample)
EP (2) EP3607962B1 (enExample)
JP (4) JP6824739B2 (enExample)
KR (4) KR20230051721A (enExample)
CN (4) CN111920939A (enExample)
AU (3) AU2014364528C1 (enExample)
BR (1) BR112016013961A2 (enExample)
CA (1) CA2933601A1 (enExample)
CY (1) CY1122604T1 (enExample)
DK (2) DK3607962T3 (enExample)
EA (1) EA037823B1 (enExample)
ES (2) ES2771749T3 (enExample)
FI (1) FI3607962T3 (enExample)
HR (2) HRP20251406T1 (enExample)
HU (1) HUE047062T2 (enExample)
IL (1) IL246162B (enExample)
LT (2) LT3607962T (enExample)
MX (2) MX380968B (enExample)
NZ (1) NZ721089A (enExample)
PL (2) PL3607962T3 (enExample)
PT (2) PT3607962T (enExample)
RS (2) RS67626B1 (enExample)
SI (2) SI2986308T1 (enExample)
SM (2) SMT202000018T1 (enExample)
WO (1) WO2015095535A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9572856B2 (en) 2009-12-16 2017-02-21 The George Washington University a Congressionally Chartered Not-for-Profit Corporation Method of treating low blood pressure
LT3607962T (lt) 2013-12-18 2026-01-12 The George Washington University, A Congressionally Chartered Not-For-Profit Corporation Vien tik angiotenzinas ii arba derinyje, skirtas hipotenzijos gydymui
TWI754225B (zh) * 2014-07-08 2022-02-01 美商拉荷亞製藥公司 治療低血壓之方法
US9919022B2 (en) 2015-03-20 2018-03-20 Arthur J. ATKINSON, JR. Use of angiotensin II (AII) receptor agonists to prevent or reduce hemodialysis-associated skeletal muscle cramps
BR112018013852A2 (pt) * 2016-01-07 2018-12-18 La Jolla Pharmaceutical Company métodos de administração de vasopressores
BR112018013847A2 (pt) * 2016-01-07 2018-12-18 La Jolla Pharma Co métodos para administrar a angiotensina ii
US11583568B2 (en) 2017-04-14 2023-02-21 La Jolla Pharma, Llc Methods for administering angiotensin II
US20190183962A1 (en) * 2017-12-15 2019-06-20 La Jolla Pharma, Llc Angiotensin compositions and methods related thereto
US20250366467A1 (en) * 2022-06-15 2025-12-04 Virginia Commonwealth University Methods for fluid resuscitation of an organ donor
WO2024129057A1 (en) * 2022-12-12 2024-06-20 Proletariat Therapeutics, Inc. Methods of treating cardiac injury

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU181008B (en) 1980-01-18 1983-05-30 Richter Gedeon Vegyeszet Process for producing angiotenzin-ii analogues of antagonistic activity containing sarcosyl-group at the 1-positon,and an alpha-hydroxy-carboxylic acid at the 8-position
US5216025A (en) * 1989-09-13 1993-06-01 Board Of Regents, The University Of Texas System Nitric oxide synthesis inhibitors for potentiating the action of pressor agents in certain hypotensive patients
US5444067A (en) 1993-08-30 1995-08-22 Merck & Co., Inc. Pharmaceutical treatment methods using angiotensin II receptor agonists bearing a thiophene moiety
WO2002098906A1 (en) 2001-06-04 2002-12-12 Human Genome Sciences, Inc. Methods and compositions for modulating ace-2 activity
US7115266B2 (en) 2001-10-05 2006-10-03 Cytos Biotechnology Ag Angiotensin peptide-carrier conjugates and uses thereof
US7785566B2 (en) 2003-11-06 2010-08-31 Ge Healthcare, Inc. Pharmaceutical compounds
NO20034952D0 (no) 2003-11-06 2003-11-06 Amersham Health As Farmasöytiske forbindelser
FR2880807B1 (fr) * 2005-01-19 2007-04-13 Aguettant Sa Lab Composition pharmaceutique injectable
WO2007040636A1 (en) 2005-09-29 2007-04-12 Fibrogen, Inc. Methods for reducing blood pressure
EP1971358A4 (en) * 2005-12-30 2010-05-26 Florey Howard Inst Methods of Treatment
US20070293552A1 (en) 2006-06-15 2007-12-20 Gorczynski Richard J Antihypertensive therapy method
WO2008130217A1 (en) * 2006-08-08 2008-10-30 Applied Nanosystems B.V. Cyclic angiotensin analogs
CN101795675A (zh) 2006-11-17 2010-08-04 达沃尔泰拉公司 使用具有Eudragit包衣的Zn/果胶珠粒进行的结肠递送
WO2009009907A1 (en) * 2007-07-18 2009-01-22 The University Of British Columbia Use of vasopressin-receptor agonists for the treatment of septic shock
EP2161030A1 (en) * 2008-09-09 2010-03-10 Rijksuniversiteit te Groningen Oxytocin formulations and uses thereof
MX2011005672A (es) 2008-11-28 2011-06-20 Abbott Lab Composiciones de anticuerpo estables y metodos para estabilizar a las mismas.
US9572856B2 (en) * 2009-12-16 2017-02-21 The George Washington University a Congressionally Chartered Not-for-Profit Corporation Method of treating low blood pressure
FR2959414B1 (fr) * 2010-04-30 2016-01-08 Luc Quintin Combinaison de molecules aux fins de traitement d'hypotension survenant au cours du choc septique, cardiogenique, ou anaphylactique refractaire, ou hemorragique terminal, apres correction de la volemie et de l'etat de mal asthmatique refractaire
AU2011279144A1 (en) 2010-07-14 2013-01-24 Cumberland Emerging Technologies, Inc Methods of treating hepatorenal syndrome and hepatic encephalopathy with thromboxane-A2 receptor antagonists
AU2014256944B2 (en) 2013-04-26 2019-06-27 La Jolla Pharma, Llc Compositions and methods for treating renal failure
LT3607962T (lt) 2013-12-18 2026-01-12 The George Washington University, A Congressionally Chartered Not-For-Profit Corporation Vien tik angiotenzinas ii arba derinyje, skirtas hipotenzijos gydymui
US20150286797A1 (en) 2014-04-02 2015-10-08 David R. Ratto System and method for administering medication
TWI754225B (zh) 2014-07-08 2022-02-01 美商拉荷亞製藥公司 治療低血壓之方法
BR112018013852A2 (pt) 2016-01-07 2018-12-18 La Jolla Pharmaceutical Company métodos de administração de vasopressores
BR112018013847A2 (pt) 2016-01-07 2018-12-18 La Jolla Pharma Co métodos para administrar a angiotensina ii
US11583568B2 (en) 2017-04-14 2023-02-21 La Jolla Pharma, Llc Methods for administering angiotensin II
US20190183962A1 (en) 2017-12-15 2019-06-20 La Jolla Pharma, Llc Angiotensin compositions and methods related thereto

Also Published As

Publication number Publication date
CN111920939A (zh) 2020-11-13
CA2933601A1 (en) 2015-06-25
EP2986308B1 (en) 2019-10-16
BR112016013961A2 (pt) 2017-10-10
KR102399383B1 (ko) 2022-05-19
EP2986308A4 (en) 2017-01-11
SMT202000018T1 (it) 2020-03-13
DK2986308T3 (en) 2020-01-27
SMT202500427T1 (it) 2026-01-12
WO2015095535A1 (en) 2015-06-25
EP2986308A1 (en) 2016-02-24
US11559559B2 (en) 2023-01-24
EA201691258A1 (ru) 2016-11-30
KR20220028125A (ko) 2022-03-08
AU2024219851A1 (en) 2024-10-10
US20190070250A1 (en) 2019-03-07
AU2014364528C1 (en) 2021-01-07
AU2014364528A1 (en) 2016-06-30
MX380968B (es) 2025-03-12
JP2017501154A (ja) 2017-01-12
KR20240154702A (ko) 2024-10-25
JP7175506B2 (ja) 2022-11-21
US20150164980A1 (en) 2015-06-18
CN119700926A (zh) 2025-03-28
PT2986308T (pt) 2020-01-21
HRP20251406T1 (hr) 2026-02-27
US9220745B2 (en) 2015-12-29
US10493124B2 (en) 2019-12-03
JP2022137224A (ja) 2022-09-21
US20190328827A1 (en) 2019-10-31
MX2020011190A (es) 2020-11-13
LT3607962T (lt) 2026-01-12
EA037823B1 (ru) 2021-05-25
US11096983B2 (en) 2021-08-24
KR20230051721A (ko) 2023-04-18
US20160129072A1 (en) 2016-05-12
AU2014364528A9 (en) 2016-07-28
HRP20200009T1 (hr) 2020-03-20
CN106061493A (zh) 2016-10-26
AU2014364528B2 (en) 2020-08-27
RS67626B1 (sr) 2026-02-27
FI3607962T3 (fi) 2025-11-24
SI3607962T1 (sl) 2026-02-27
PT3607962T (pt) 2025-11-18
US20220047669A1 (en) 2022-02-17
EP3607962A1 (en) 2020-02-12
JP2019214610A (ja) 2019-12-19
CN112546197A (zh) 2021-03-26
HUE047062T2 (hu) 2020-04-28
ES2771749T3 (es) 2020-07-07
US20180193407A1 (en) 2018-07-12
SI2986308T1 (sl) 2020-03-31
US10028995B2 (en) 2018-07-24
KR20160117437A (ko) 2016-10-10
JP2025114753A (ja) 2025-08-05
ES3055611T3 (en) 2026-02-13
CY1122604T1 (el) 2021-03-12
PL3607962T3 (pl) 2026-03-09
MX2016008108A (es) 2017-03-09
US10765722B2 (en) 2020-09-08
IL246162A0 (en) 2016-07-31
LT2986308T (lt) 2020-03-25
JP6824739B2 (ja) 2021-02-03
PL2986308T3 (pl) 2020-05-18
WO2015095535A9 (en) 2016-07-14
IL246162B (en) 2020-03-31
RS59804B1 (sr) 2020-02-28
DK3607962T3 (da) 2025-11-17
AU2020277230A1 (en) 2020-12-24
US20230226141A1 (en) 2023-07-20
EP3607962B1 (en) 2025-08-13

Similar Documents

Publication Publication Date Title
MX2020011190A (es) Angiotensina ii sola o en combinacion para usarse en el tratamiento de hipotension.
BR112015022197A2 (pt) tratamento de cataplexia
MX365950B (es) Compuestos de piridazinona y metodos para el tratamiento de la fibrosis quistica.
PH12014501997A1 (en) Esketamine for the treatment of treatment-refractory or treatment-resistant depression
NZ774222A (en) Methods of treating and preventing endothelial dysfunction using bardoxolone methyl or analogs thereof
EA201491500A1 (ru) Способы лечения фиброза
EA201591507A1 (ru) Лечение рассеянного склероза лахинимодом
EA201591424A1 (ru) Способы лечения дефицита железа растворимым пирофосфатом железа
EA202091446A1 (ru) Способы лечения хронических воспалительных заболеваний
MX2017000306A (es) Metodos para tratar hipotension.
UA117243C2 (uk) Застосування ландіололу гідрохлориду у тривалому лікуванні тахіаритмії
MX382044B (es) Oxabicicloheptanos y oxabicicloheptenos para el tratamiento de trastornos depresivos y de estrés.
MX2016006256A (es) Tratamiento de glaucoma usando laquinimod.
WO2014107685A3 (en) Compositions and methods for using huperzine and analogs thereof
MX2021014120A (es) Tratamiento de los sintomas asociados a terapia privacion de androgenos.
MX374354B (es) Método de curación de heridas.
PH12016501101A1 (en) Veliparib in combination with carboplatin for the treatment of triple negative breast cancer
EA202092463A1 (ru) Ангиотензин ii самостоятельно или в комбинации для лечения гипотензии
MX2021001394A (es) Metodo para mejorar la eficacia de un agente anticanceroso.
EA201892389A1 (ru) Офтальмологическая композиция, содержащая синергическую комбинацию гликогена и гиалуроновой кислоты или ее соли
MX2017015658A (es) Composicion de peptidos multiples.
EA201991119A1 (ru) Фармацевтическая композиция, способы лечения и ее применения
UA106472U (uk) Засіб для лікування дерматологічних захворювань
UA102764U (uk) Спосіб лікування гіповолемії у хірургічних хворих

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 18 DEC 2024 BY COMPUTER PACKAGES INC

Effective date: 20231217

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 18 DEC 2025 BY COMPUTER PACKAGES INC

Effective date: 20241130